Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 2Phase 1 2

Status

Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms 1Anemia, Iron-Deficiency 1Anaemia in Ovarian Carcinoma 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × iron isomaltoside 1000 × Clear all
NCT06248749 2024-02-08

Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer

University of Saskatchewan

Phase 3 Not yet recruiting
200 enrolled
Gynecologic

Anaemia in Ovarian Carcinoma

NCT05467319 2022-07-20

FORGE

Alberta Health Services, Calgary

Phase 3 Unknown
82 enrolled
Classical hematology

Anemia, Iron-Deficiency

NCT01145638 2015-12-03

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Pharmacosmos A/S

Phase 3 Completed
350 enrolled 9 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡